Coya Therapeutics, Inc Common Stock

Yahoo Finance • 4 days ago

Coya Therapeutics resubmits IND application for ALS Phase 2 study to FDA

Coya Therapeutics , Inc. (NASDAQ:COYA), a $96 million market cap biotech company, announced Monday that it has resubmitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration for a planned Phase 2 clinic... Full story

Yahoo Finance • 3 months ago

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious vi... Full story

Yahoo Finance • 3 months ago

Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Coya Therapeutics, Inc. (NASDAQ:COYA) stands against other top healthcare stocks t... Full story

Yahoo Finance • 2 years ago

Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Under the Agreement, Dr. Reddy’s will obtain commercialization rights for COYA 302 in the United States, Canada, the European Union and the United Kingdom, for patients with ALS COYA will be responsible for development, including the cond... Full story